This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.
Tovecimig is a bispecific antibody targeting DLL4 and VEGF-A, showing clinical benefit in patients with advanced biliary tract, colorectal, and gastric cancers after prior targeted therapies.
CTX-8573 is a common light chain-based NKp30 x BCMA bispecific antibody that targets BCMA-positive tumor and plasma cells, recruiting and activating innate cells via NKp30 and CD16a receptors.
CTX-471 is a fully human monoclonal antibody that binds and activates a novel epitope of the co-stimulatory receptor CD137, also known as 4-1BB, a member of the tumor necrosis factor receptor superfamily.
Compass uses its antibody discovery engine to explore immune system drug targets and empirically test combinations, translating findings into tailored bispecific antibodies with monoclonal-like production.
